Gentium Receives Positive Opinion From EMA's COMP for Defibrotide for the Prevention of GvHD
October 10, 2013 17:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Medicines Agency's Committee for Orphan Medicinal Products...
Salvatore Calabrese Appointed to Chief Operating Officer at Gentium S.p.A.
October 02, 2013 06:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has promoted Salvatore Calabrese to the position of Chief Operating...
Gentium Reports First Half 2013 Financial Results
August 13, 2013 06:00 ET
|
Gentium S.p.A.
Positive Opinion from EMA's CHMP for Defitelio®.
Defibrotide revenues up 26% to EUR 14.26 million (USD 18.55 million) for the six-month period ended June 30, 2013 from EUR 11.35 million...
Gentium to Report First Half 2013 Financial Results
August 01, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the first half of 2013 on...
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
July 26, 2013 07:40 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, July 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, following its request for re-examination, the European Medicines Agency's...
Gentium Provides EMA Update
July 26, 2013 07:16 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, July 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced that today, Friday, July 26, 2013, it will provide update on Defibrotide Marketing...
Gentium Provides Update on Re-Examination of Defibrotide MAA to EMA
June 04, 2013 06:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, June 4, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, the Company has filed the documentation requesting a Re-examination of the...
Gentium Reports First Quarter Financial Results
May 14, 2013 07:00 ET
|
Gentium S.p.A.
Defibrotide usage increased by 32% to EUR 6.49 million (US$ 8.31 million).
Product sales of EUR 7.54 million (US$ 9.65 million) for the three month period ended March 31, 2013, recording an...
Gentium to Request Re-Examination of CHMP Opinion on Defibrotide
April 16, 2013 06:30 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, April 16, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has requested a re-examination of the negative opinion adopted, by the...
Satellite Symposia on Defibrotide and Veno-Occlusive Disease at EBMT 39th Annual Meeting
April 09, 2013 16:30 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, April 9, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of two...